Kalaris Therapeutics Inc (KLRS)

$9.13 -0.13 (-1.35%)
Market Cap 173.09M
Revenue (ttm) 0.00
Net Income (ttm) -58.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 101,300
Avg Vol 152,438
Day's Range N/A - N/A
Shares Out 18.70M
Stochastic %K 23%
Beta -0.04
Analysts Strong Sell
Price Target $19.00

Company Profile

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

Industry: Biotechnology
Sector: Healthcare
Address:
628 Middlefield Road, Palo Alto, United States
WallStArb
WallStArb Dec. 29 at 4:18 PM
$KLRS looking for 3.50 - 4.20
0 · Reply
WallStArb
WallStArb Dec. 29 at 3:07 PM
$KLRS expect this to trade back down near net cash out 90d - this never had a PIPE when they did the reverse so I expect the $50M essentially covers that now - curious why the investors didn’t do the pipe prior to the data - now it’s a 12 month wait for next major data points
0 · Reply
ZenithZulu
ZenithZulu Dec. 25 at 2:57 PM
$KLRS Forward returns depend heavily on whether management can deliver consistent operational results. Execution gaps should narrow meaningfully over coming quarters. Visible traction across segments would strengthen the thesis. The next phase will be defined less by vision and more by delivery.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 9:43 AM
$KLRS
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 12:40 PM
Chardan Capital has updated their rating for Kalaris Therapeutics ( $KLRS ) to Buy with a price target of 19.
0 · Reply
DonCorleone77
DonCorleone77 Dec. 23 at 10:49 AM
$KLRS Kalaris Therapeutics initiated with a Buy at Chardan Chardan initiated coverage of Kalaris Therapeutics with a Buy rating and $19 price target. The firm cites the commercial potential of the company's lead candidate TH103 in wet age-related macular degeneration for the Buy rating. Kalaris has further opportunities to expand into diabetic retinopathy, diabetic macular edema, and retinal vein occlusion, the analyst tells investors in a research note.
0 · Reply
StockScanners
StockScanners Dec. 20 at 6:29 PM
$KLRS reached 1.88
0 · Reply
WallStArb
WallStArb Dec. 19 at 9:06 PM
$KLRS I don’t own this anymore and I am not interested in it any longer was a one time trade. Started to accumulate a couple new names and added to $ASMB thiscmorning for spring updates and data points
2 · Reply
www_larval_com
www_larval_com Dec. 18 at 3:07 PM
Lookie here; $KLRS has dropped -7% lower to -2% (~206Kv) moments ago, follow for more volatility.
0 · Reply
Orlandotrader
Orlandotrader Dec. 18 at 2:15 PM
$KLRS Would not be surprised if this runs up today based on the Great Placement of 10$. Someone payed up for this. Not sure why. Still trying to determine dosing.
1 · Reply
Latest News on KLRS
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Dec 19, 2025, 12:04 PM EST - 10 days ago

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Dec 18, 2025, 12:47 PM EST - 11 days ago

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Dec 17, 2025, 5:59 PM EST - 12 days ago

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Dec 17, 2025, 4:01 PM EST - 12 days ago

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 24, 2025, 8:00 AM EST - 5 weeks ago

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 12, 2025, 8:00 AM EST - 6 weeks ago

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Nov 3, 2025, 7:30 AM EST - 2 months ago

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

Oct 30, 2025, 8:00 AM EDT - 2 months ago

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Sep 15, 2025, 3:26 PM EDT - 3 months ago

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Sep 15, 2025, 8:00 AM EDT - 3 months ago

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Jun 2, 2025, 8:00 AM EDT - 7 months ago

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Kalaris to Participate at Stifel Ophthalmology Forum

May 23, 2025, 11:03 AM EDT - 7 months ago

Kalaris to Participate at Stifel Ophthalmology Forum

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 14, 2025, 8:00 AM EDT - 8 months ago

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Apr 4, 2025, 8:00 AM EDT - 9 months ago

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Kalaris Announces Closing of Merger with AlloVir

Mar 18, 2025, 4:21 PM EDT - 10 months ago

Kalaris Announces Closing of Merger with AlloVir

ALVR

WallStArb
WallStArb Dec. 29 at 4:18 PM
$KLRS looking for 3.50 - 4.20
0 · Reply
WallStArb
WallStArb Dec. 29 at 3:07 PM
$KLRS expect this to trade back down near net cash out 90d - this never had a PIPE when they did the reverse so I expect the $50M essentially covers that now - curious why the investors didn’t do the pipe prior to the data - now it’s a 12 month wait for next major data points
0 · Reply
ZenithZulu
ZenithZulu Dec. 25 at 2:57 PM
$KLRS Forward returns depend heavily on whether management can deliver consistent operational results. Execution gaps should narrow meaningfully over coming quarters. Visible traction across segments would strengthen the thesis. The next phase will be defined less by vision and more by delivery.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 9:43 AM
$KLRS
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 12:40 PM
Chardan Capital has updated their rating for Kalaris Therapeutics ( $KLRS ) to Buy with a price target of 19.
0 · Reply
DonCorleone77
DonCorleone77 Dec. 23 at 10:49 AM
$KLRS Kalaris Therapeutics initiated with a Buy at Chardan Chardan initiated coverage of Kalaris Therapeutics with a Buy rating and $19 price target. The firm cites the commercial potential of the company's lead candidate TH103 in wet age-related macular degeneration for the Buy rating. Kalaris has further opportunities to expand into diabetic retinopathy, diabetic macular edema, and retinal vein occlusion, the analyst tells investors in a research note.
0 · Reply
StockScanners
StockScanners Dec. 20 at 6:29 PM
$KLRS reached 1.88
0 · Reply
WallStArb
WallStArb Dec. 19 at 9:06 PM
$KLRS I don’t own this anymore and I am not interested in it any longer was a one time trade. Started to accumulate a couple new names and added to $ASMB thiscmorning for spring updates and data points
2 · Reply
www_larval_com
www_larval_com Dec. 18 at 3:07 PM
Lookie here; $KLRS has dropped -7% lower to -2% (~206Kv) moments ago, follow for more volatility.
0 · Reply
Orlandotrader
Orlandotrader Dec. 18 at 2:15 PM
$KLRS Would not be surprised if this runs up today based on the Great Placement of 10$. Someone payed up for this. Not sure why. Still trying to determine dosing.
1 · Reply
briefingcom
briefingcom Dec. 18 at 1:46 PM
$KLRS: Kalaris Therapeutics prices $50.0 mln private placement consisting of common stock and warrants https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251218042942KLRS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
notreload_ai
notreload_ai Dec. 18 at 10:41 AM
$KLRS secured $50 million in oversubscribed funding at a premium to support its eye drug, TH103. However, small trials, safety concerns, and lengthy timelines create uncertainty.
0 · Reply
StockScanners
StockScanners Dec. 18 at 5:32 AM
$KLRS keep watch if this holds above 9.80
0 · Reply
JohnTrack
JohnTrack Dec. 18 at 1:00 AM
$KLRS it seems to be a good price for the offering https://www.rapidticker.com/news/klrs-kalaris-therapeutics-announces-oversubscribed-500-f1f56
1 · Reply
Godwins26
Godwins26 Dec. 18 at 12:44 AM
Watchlist for the week 😊 $OPTT $PCSA $JMG $SMX $KLRS
0 · Reply
JohnTrack
JohnTrack Dec. 18 at 12:03 AM
$KLRS monitoring flush and recover!
0 · Reply
fallondpicks
fallondpicks Dec. 17 at 10:36 PM
19 #stockbreakouts $ABM, $DBVT (gap), $FBRX, $KLRS, $TWO (gap, base and 200-day MA). One sub-$1. Four $1-2.
0 · Reply
notreload_ai
notreload_ai Dec. 17 at 10:20 PM
$KLRS reports Phase 1a data for TH103 AMD treatment, but manufacturing issues, limited patient sample, and uncertain durability claims warrant caution from investors. https://notreload.xyz/kalaris-th103-early-results-raise-more-questions-than-answers/
0 · Reply
JohnTrack
JohnTrack Dec. 17 at 10:15 PM
$KLRS positive initial phase 1a data https://www.rapidticker.com/news/klrs-kalaris-therapeutics-reports-positive-initial-d2e121
0 · Reply
Orlandotrader
Orlandotrader Dec. 17 at 9:36 PM
$KLRS Well Well I smelled Right!!! Data. Good but still way too early to be in this one. Second Half 2026 till further Updates on Ascending Doses for 1/2 Trial. Glad I sold at 10.50. See you later next year.
0 · Reply
topstockalerts
topstockalerts Dec. 17 at 8:00 PM
Top Gainers PT2 $GVH $DBVT $BENF $IMG $KLRS
0 · Reply
50shadesoftrades
50shadesoftrades Dec. 17 at 7:25 PM
$JMG $PCSA $MGRT $BENF $KLRS Intraday gainers
1 · Reply